Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
letter
. 2020 Jun 24;190(3):e130–e133. doi: 10.1111/bjh.16906

A case series of Monoclonal Gammopathy of Undetermined Significance and COVID‐19

Jesus D Gonzalez‐Lugo 1, Lizamarie Bachier‐Rodriguez 1, Mendel Goldfinger 1, Aditi Shastri 1, R Alejandro Sica 1, Kira Gritsman 1, Vikas Mehta 2, Rafi Kabarriti 3, Sanjay Goel 1, Amit Verma 1, Ira Braunschweig 1, Noah Kornblum 1,, Ioannis Mantzaris 1,
PMCID: PMC7300638  PMID: 32479664

Monoclonal Gammopathy of Undetermined Significance (MGUS) is a pre‐malignant clonal plasma cell disorder, with 25–30% life‐long risk of progression to multiple myeloma (MM). 1 It is usually asymptomatic, but infrequently associated with several serious conditions, such as neuropathies, glomerulonephritis and acquired angioedema. 2 Moreover, a higher risk of infection and deep venous thrombosis has been reported in patients with MGUS. 3 , 4

In recent studies of SARS‐CoV‐2 infection (COVID‐19) in cancer, a higher fatality rate was found, 5 especially in haematologic malignancies. 6 While not an overt haematologic malignancy, MGUS falls within the spectrum of plasma cell dyscrasias, and has the potential to disrupt immunity and coagulation. 3 , 4 Therefore, MGUS could affect the course and outcome of COVID‐19; however, such association remains unknown.

We describe seven patients diagnosed with MGUS who tested positive for COVID‐19 from 18 March through 8 April, 2020, at Montefiore Health System, that was the epicentre of the COVID‐19 pandemic in the Bronx, New York (Table I). All cases were positive by real‐time reverse‐transcriptase polymerase chain reaction of nasopharyngeal swabs.

Table I.

Baseline characteristics, laboratory findings and clinical course of COVID‐19 patients with MGUS.

Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age (years) 59 66 83 71 81 76 92
Gender Male Female Male Male Female Male Male
Race/Ethnicity Hispanic White AA Other AA Hispanic AA
Comorbidities

DM

HTN

HTN

CLD

DM

HTN

CKD

HTN

DM

HTN

CLD

CKD

CHF

DM

HTN

CKD

DM

HTN

CKD

Dementia

Immunoglobulin Subtype IgG Kappa IgG Lambda IgA Kappa IgM Lambda IgG Lambda IgA Lambda IgG Kappa
MGUS risk stratification Low‐intermediate Low High‐intermediate Low‐intermediate Low Low‐intermediate Low‐intermediate
NH resident No No No No No No Yes
Lab Tests
Haemoglobin, g/l
Prior to admission 125 127 118 135 104 125 112
Minimum 99 115 82 107 81
Platelets, x109/l
Prior to admission 389 317 210 116 282 315 191
Minimum 156 89 185 301 141
ANC (x109/l)
Prior to admission 6·4 6·4 2·9 1·2 4·3 2·2 1·1
Minimum 1·2 5·3 2·3 2·8 0·3
ALC (x109/l)
Prior to admission 3·9 1·3 3·4 1·3 1·0 1·6 1·1
Minimum creatinine, mg/dl 0·2 1·6 0·6 0·4 0·4
Prior to admission 0·8 0·7 1·6 0·9 2·2 1·2 1·1
Maximum D‐dimer, μg/ml 0·8 2·77 2·94 12·7 1·7
Maximum ferritin, ng/ml 20 1·38 2·14 20
Maximum CRP, mg/dl 1525 527 1575 766
Maximum 25·1 5·6 7 6·2
Clinical course
Hospital admission No Yes Yes No Yes Yes Yes
ICU admission No No No No No No No
Intubation No No No No No No No
Dialysis No No No No No Yes No
LOS, days 16 8 11 25 13
Outcome Recovered Recovered Recovered Recovered Recovered Recovered Deceased

AA: African American, ALC: Absolute Lymphocyte Count, ANC: Absolute Neutrophil Count, CHF: Congestive Heart Failure, CKD: Chronic Kidney Disease, CLD: Chronic Lung Disease, DM: Diabetes Mellitus, HTN: Hypertension, LOS: Length of stay, MGUS: Monoclonal Gammopathy of Undetermined Significance, NH: Nursing Home.

MGUS Risk Stratification per Mayo Clinic Criteria.

Case 1: A 59‐year‐old Hispanic man with low‐ to intermediate‐risk IgG‐kappa MGUS, diabetes mellitus (DM) and hypertension (HTN), presented to the Emergency Department (ED) with three days of dry cough, subjective fever and myalgias. He was normotensive, afebrile, with a room‐air oxygen saturation (SpO2) of 98%. He did not require hospital admission, was followed‐up one month later and his symptoms had resolved.

Case 2: A 66‐year‐old Caucasian woman with low‐risk IgG‐lambda MGUS, HTN and bronchiectasis presented to the ED with one week of productive cough, subjective fever, wheezing and diarrhoea. She was normotensive, febrile to 38.9°C, with a room‐air SpO2 of 98%. Her chest X‐ray (CXR) showed chronic changes. She was hospitalized, started on broad‐spectrum antibiotics for presumed superimposed pneumonia, and a course of hydroxychloroquine and lopinavir/ritonavir per institutional protocol. Her hospitalization was complicated by non‐infectious diarrhoea, which eventually improved, and was discharged to a rehabilitation facility after a 16‐day hospitalization.

Case 3: An 83‐year‐old African American (AA) man with high‐ to intermediate‐risk IgA‐kappa MGUS, HTN, DM and chronic kidney disease (CKD), presented with altered mental status (AMS) and lethargy noticed a few hours prior to presentation, and six days of dry cough and malaise. He was normotensive, afebrile, with a room‐air SpO2 of 80%, which corrected to 96% on a nasal cannula (NC) (4 l/min). His CXR revealed multifocal bilateral infiltrates. Serum glucose was 884 mg/dl. He was started on intravenous fluids and insulin for his hyperosmolar hyperglycaemic state. D‐dimers peaked at 20 μg/ml. He received broad‐spectrum antibiotics for potential bacterial superinfection. His confusion gradually resolved, oxygen requirements improved and he was discharged home on hospital day eight.

Case 4: A 71‐year‐old man with low‐ to intermediate‐risk IgM‐lambda MGUS and HTN presented to his general practitioner’s office with dry cough. He was instructed to self‐isolate at home, was followed‐up one month later and noted his symptoms had resolved.

Case 5: An 81‐year‐old AA woman with low‐risk IgG‐lambda MGUS, HTN, DM, CKD, congestive heart failure, and pulmonary sarcoidosis presented to the ED with 10 days of dry cough and dyspnoea. She was hypotensive (90/53), afebrile, with a room‐air SpO2 of 89% which improved to 99% on a non‐rebreather mask (NRB). CXR showed left lung base atelectasis. Acute kidney injury (AKI) was noted. She was hospitalized, started on intravenous fluids with resolution of hypotension, and treated with hydroxychloroquine per institutional protocol. She was transitioned to NC on hospital day 2. Her renal function and oxygenation gradually improved, and she was discharged to a rehabilitation facility after an 11‐day hospitalization.

Case 6: A 76‐year‐old Hispanic man with low‐ to intermediate‐risk IgA‐lambda MGUS, HTN, DM and CKD presented to the ED with five days of dry cough and dyspnoea. He was hypertensive (181/78 mm Hg), febrile (38.3°C), with a room‐air SpO2 of 96%. His CXR showed bibasilar infiltrates. AKI with hyperkalaemia was noted. He was hospitalized and later developed non‐ST‐elevation myocardial infarction, managed conservatively. His renal function deteriorated and on hospital day 6 haemodialysis was initiated. His renal function gradually improved and he was discharged home on hospital day 25.

Case 7: A 92‐year‐old AA man, nursing‐home‐resident with low‐ to intermediate‐risk IgG‐kappa MGUS, HTN, DM, CKD, epilepsy and dementia presented to the ED with AMS and lethargy noticed a few hours prior to presentation. He had a dry cough, dyspnoea and malaise for one week. He was hypertensive (158/88 mm Hg), afebrile, with a room‐air SpO2 of 96%. On examination he was using accessory respiratory muscles. The patient had do‐not‐resuscitate and do‐not‐intubate orders and was therefore placed on a NRB. his CXR showed left mid‐lower lobe infiltrates. He was admitted, started on broad‐spectrum antibiotics and additionally treated for decompensated heart failure. D‐dimers peaked at 20 μg/ml. Finally, his family opted for comfort care and he expired on hospital day 13.

COVID‐19 is a heterogeneous disease that ranges from asymptomatic in some patients to fatal in others. Advanced age, male sex and comorbidities, such as HTN and DM have been identified as risk factors for adverse prognosis. Significant coagulopathy has been observed in severe cases, and elevated D‐dimer levels have been shown to have prognostic significance. 7 , 8 , 9 , 10 , 11 In a study performed at our institution, patients with haematologic malignancies and COVID‐19 had a higher mortality rate than non‐cancer patients. 6

We wanted to investigate the effects that MGUS might have on patients with COVID‐19. Our patients were older adults with an age range between 59 and 92 years. They all had underlying conditions, identified as high‐risk comorbidities, yet none of the patients required mechanical ventilation or ICU management, and with the exception of one fatality, they all eventually recovered (Table I). The only fatality was a patient with multiple risk factors, including male sex, advanced age, nursing home residency, multiple comorbidities and a very elevated D‐dimer.

MGUS represents the earliest stage of plasma cell dyscrasia and is generally an asymptomatic phase of the disease spectrum. Still, some studies suggest MGUS patients manifest increased susceptibility to bacterial and viral infections, as well as coagulation abnormalities. 3 , 4 Whether these perturbations of immunity and coagulation have the potential to impact the clinical trajectory of COVID‐19 remains to be examined with large‐scale data. This small case series seems to suggest that MGUS may not pose additional risks for poor outcome in COVID‐19 infection.

Conflicts of interest

The authors declare no competing financial interests.

Author contributions

AV, NK and IM conceived the research; AV, VM, RK, LBR, MG, AS, RAS, KG, IB and SJ identified the cases and provided clinical information; JGL collected the data; JGL, NK, IM and AV wrote the manuscript. All the authors reviewed and approved the final version of the manuscript.

Contributor Information

Noah Kornblum, Email: nkornblu@montefiore.org.

Ioannis Mantzaris, Email: imantzar@montefiore.org.

References

  • 1. Blade J, Rosinol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia. 2008;22(9):1651–7. [DOI] [PubMed] [Google Scholar]
  • 2. Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood. 2018;131(2):163–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population‐based study. Haematologica. 2012;97(6):854–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9):3582–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS‐COV‐ 2: A Multicenter Study during the COVID‐19 Outbreak. Cancer Discov. 2020. 10.1158/2159-8290.CD-20-0422 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Mehta V, Goel S, Kabarriti R, Cole D, et al. Fatality rate of cancer patients with COVID‐19 in a New York Hospital System. Cancer Discov. 2020. 10.1158/2159-8290.CD-20-0516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID‐19 in the New York City Area. JAMA. 2020;323(20):2052–59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID‐19: evidence from meta‐analysis. Aging (Albany NY). 2020;12(7):6049–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Bowles L, Platton S, Yartey N, et al. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with COVID‐19. N Engl J Med. 2020. 10.1056/NEJMc2013656 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Fauci AS, Lane HC, Redfield RR. COVID‐19 ‐ Navigating the Uncharted. N Engl J Med. 2020;382(13):1268–9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Haematology are provided here courtesy of Wiley

RESOURCES